SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employe ...

Basel, June 23, 2025 – Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc. (“Regulus”), in exchange for (i) $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus (ii) one co ...

23 June 2025, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR We have been notified that, Aurora Value Fund, a fund organized and existing under the laws of Liechtenstein, registered with the Liechtenstein Investment Fund Association (LAFV) under register number FL-0002.305.581-2 represented and acting through its management company CAIAC Fund Management AG, a company incorporated under the laws of Liechtenstein, with registered office at Haus Atzig, Industriestrasse 2, 9487 Bendern, Liechtens ...

Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show NXT007 achieved no bleeds requiring treatment in the highest dose groups in people with haemophilia A1 The NXT007 clinical development programme aims to normalise haemostasis and minimise treatment burden2,3Three phase III clinical studies on NXT007, a next-generation bispecific antibody, set to begin in 20261 Basel, 23 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positiv ...

Ad hoc announcement pursuant to Art. 53 LR Idorsia to receive USD 50 million (an additional USD 30 million) approval milestone payment in return for a reduction in Simcere potential sales milestones and tiered royalty payments. Allschwil, Switzerland – June 23, 2025Idorsia Ltd. (SIX: IDIA) today announced that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has received approval for QUVIVIQ® (daridorexant) from the Chinese National Medical Products Administration for the treatment of adult patients w ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and prolonged PFS compared to VRd aloneIf approved, it would represent the fourth indication in the EU and second in the front-line setting globally Paris, June 23, 2025. The European Medicines Agency’s Committee for Medicinal Products for Human Use ( ...

Core Insights - The article discusses potential investment opportunities in YORW, indicating a possible long position within the next 72 hours [1]. Group 1 - The author expresses a personal opinion on the investment landscape without any compensation from the companies mentioned [1]. - There is an emphasis on the necessity for investors to conduct their own due diligence and research prior to making any investment decisions [2]. - The article clarifies that past performance does not guarantee future results, and no specific investment recommendations are provided [3].

Core Viewpoint - Mortgage REITs offer a double-digit yield, making them appealing to income investors, while the broader REIT sector has faced challenges in recent years [1] Group 1 - Mortgage REITs are traditionally attractive to income investors due to their ability to generate high yields [1] - The REIT sector has been largely inactive in recent years, indicating potential challenges or shifts in market dynamics [1]

Core Insights - The share price of a certain company has decreased by over 45% in the past 12 months, returning to levels seen in 2012, specifically between $125.5 and $130 [1] Group 1: Company Overview - Allka Research has over two decades of experience in investment, focusing on identifying undervalued assets in various sectors including ETFs, commodities, technology, and pharmaceuticals [1] - The company adopts a conservative investment approach, which distinguishes it in the market and aims to deliver substantial returns and strategic insights to clients [1] Group 2: Mission and Community Engagement - Allka Research is committed to simplifying investment strategies, making them accessible to both seasoned investors and newcomers [1] - The company seeks to empower individuals financially by sharing knowledge and analyses through the Seeking Alpha platform, aiming to inspire confidence among readers [1]

Core Insights - Marvell Technology showcased its advanced custom chips and industry-first 2nm SRAM at the "Custom AI Investor Day" event, highlighting significant partnerships with Amazon and Microsoft [1] Group 1: Company Developments - Marvell Technology's custom chips are designed to meet the growing demand for AI applications, indicating a strong market position [1] - The introduction of 2nm SRAM technology positions Marvell as a leader in semiconductor innovation [1] Group 2: Industry Impact - The partnerships with major players like Amazon and Microsoft suggest that Marvell is well-integrated into the AI ecosystem, potentially driving future revenue growth [1]